...
search icon
ocx-img

OncoCyte Corp, Common Stock

OCX

NASDAQ

$2.56

+$0.18

(7.56%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$73.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
73.91K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.00
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.92 L
$3.48 H
$2.56

About OncoCyte Corp, Common Stock

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameOCXSectorS&P500
1-Week Return27.36%-0.03%1.53%
1-Month Return19.07%4.56%4.75%
3-Month Return-8.57%1.29%2.77%
6-Month Return-15.23%-3.54%12.18%
1-Year Return-14.38%1.59%22.34%
3-Year Return-91.74%13.55%38.91%
5-Year Return-94.9%40.85%80.7%
10-Year Return-98.42%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue16.00K1.22M7.73M958.00K1.50M[{"date":"2019-12-31","value":0.21,"profit":true},{"date":"2020-12-31","value":15.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.4,"profit":true},{"date":"2023-12-31","value":19.45,"profit":true}]
Cost of Revenue344.00K1.85M7.54M976.00K1.09M[{"date":"2019-12-31","value":4.56,"profit":true},{"date":"2020-12-31","value":24.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.95,"profit":true},{"date":"2023-12-31","value":14.46,"profit":true}]
Gross Profit(344.00K)(639.00K)188.00K(18.00K)413.00K[{"date":"2019-12-31","value":-83.29,"profit":false},{"date":"2020-12-31","value":-154.72,"profit":false},{"date":"2021-12-31","value":45.52,"profit":true},{"date":"2022-12-31","value":-4.36,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(2150.00%)(52.55%)2.43%(1.88%)27.48%[{"date":"2019-12-31","value":-7824.33,"profit":false},{"date":"2020-12-31","value":-191.24,"profit":false},{"date":"2021-12-31","value":8.85,"profit":true},{"date":"2022-12-31","value":-6.84,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses22.24M33.08M47.13M30.31M25.64M[{"date":"2019-12-31","value":47.18,"profit":true},{"date":"2020-12-31","value":70.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":64.31,"profit":true},{"date":"2023-12-31","value":54.39,"profit":true}]
Operating Income(22.24M)(29.71M)(46.95M)(18.00M)(25.14M)[{"date":"2019-12-31","value":-2223900000,"profit":false},{"date":"2020-12-31","value":-2971100000,"profit":false},{"date":"2021-12-31","value":-4694600000,"profit":false},{"date":"2022-12-31","value":-1799700000,"profit":false},{"date":"2023-12-31","value":-2513600000,"profit":false}]
Total Non-Operating Income/Expense112.00K(1.73M)645.00K(692.00K)377.00K[{"date":"2019-12-31","value":17.36,"profit":true},{"date":"2020-12-31","value":-267.75,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-107.29,"profit":false},{"date":"2023-12-31","value":58.45,"profit":true}]
Pre-Tax Income(22.43M)(31.19M)(73.36M)(18.61M)(24.86M)[{"date":"2019-12-31","value":-2242600000,"profit":false},{"date":"2020-12-31","value":-3118600000,"profit":false},{"date":"2021-12-31","value":-7335800000,"profit":false},{"date":"2022-12-31","value":-1861200000,"profit":false},{"date":"2023-12-31","value":-2485500000,"profit":false}]
Income Taxes(97.00K)(1.25M)(9.26M)54.83M2.93M[{"date":"2019-12-31","value":-0.18,"profit":false},{"date":"2020-12-31","value":-2.29,"profit":false},{"date":"2021-12-31","value":-16.89,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":5.34,"profit":true}]
Income After Taxes(22.33M)(29.93M)(64.10M)(73.44M)(27.78M)[{"date":"2019-12-31","value":-2232900000,"profit":false},{"date":"2020-12-31","value":-2993200000,"profit":false},{"date":"2021-12-31","value":-6409700000,"profit":false},{"date":"2022-12-31","value":-7344000000,"profit":false},{"date":"2023-12-31","value":-2778100000,"profit":false}]
Income From Continuous Operations(22.43M)(29.93M)(64.10M)(18.61M)(20.88M)[{"date":"2019-12-31","value":-2242600000,"profit":false},{"date":"2020-12-31","value":-2993200000,"profit":false},{"date":"2021-12-31","value":-6409700000,"profit":false},{"date":"2022-12-31","value":-1861200000,"profit":false},{"date":"2023-12-31","value":-2088000000,"profit":false}]
Income From Discontinued Operations---(54.29M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-5429000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(22.33M)(29.93M)(64.10M)(73.44M)(27.78M)[{"date":"2019-12-31","value":-2232900000,"profit":false},{"date":"2020-12-31","value":-2993200000,"profit":false},{"date":"2021-12-31","value":-6409700000,"profit":false},{"date":"2022-12-31","value":-7344000000,"profit":false},{"date":"2023-12-31","value":-2778100000,"profit":false}]
EPS (Diluted)(0.42)(0.46)(0.44)(0.66)(3.93)[{"date":"2019-12-31","value":-42,"profit":false},{"date":"2020-12-31","value":-46,"profit":false},{"date":"2021-12-31","value":-44,"profit":false},{"date":"2022-12-31","value":-66,"profit":false},{"date":"2023-12-31","value":-393,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OCX
Cash Ratio 0.37
Current Ratio 0.53
Quick Ratio 0.50

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OCX
ROA (LTM) -18.84%
ROE (LTM) -165.32%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OCX
Debt Ratio Lower is generally better. Negative is bad. 0.86
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.14

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OCX
Trailing PE NM
Forward PE NM
P/S (TTM) 103.26
P/B 7.54
Price/FCF NM
EV/R 104.15
EV/Ebitda NM
PEG NM

FAQs

What is OncoCyte Corp share price today?

OncoCyte Corp (OCX) share price today is $2.56

Can Indians buy OncoCyte Corp shares?

Yes, Indians can buy shares of OncoCyte Corp (OCX) on Vested. To buy OncoCyte Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of OncoCyte Corp be purchased?

Yes, you can purchase fractional shares of OncoCyte Corp (OCX) via the Vested app. You can start investing in OncoCyte Corp (OCX) with a minimum investment of $1.

How to invest in OncoCyte Corp shares from India?

You can invest in shares of OncoCyte Corp (OCX) via Vested in three simple steps:

  • Click on Sign Up or Invest in OCX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in OncoCyte Corp shares
What is OncoCyte Corp 52-week high and low stock price?

The 52-week high price of OncoCyte Corp (OCX) is $3.48. The 52-week low price of OncoCyte Corp (OCX) is $1.92.

What is OncoCyte Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of OncoCyte Corp (OCX) is 7.54

What is the Market Cap of OncoCyte Corp?

The market capitalization of OncoCyte Corp (OCX) is $73.21M

What is OncoCyte Corp’s stock symbol?

The stock symbol (or ticker) of OncoCyte Corp is OCX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top